When: Confirmed close >$1,285 on volume >3M shares

Then: Half-size first tranche with stop at breakout day's low

When: Position >~5% NAV on retest of $1,280 on declining volume

Then: Trim back to ~5% NAV

When: Closing basis below $1,170 (just below rising 50 SMA at ~$1,178)

Then: Tactical reassessment/exit

When: Close <$1,051 (200 SMA) OR GLP-1 class-wide safety event OR retatrutide Phase 3 disappointment

Then: Full exit required

HOLD at 3-5% sizing; wait for pullback entry at $1,200-$1,225 with hard stop at $1,170 on daily close

• PEG ratio of 1.61 is irrelevant at all-time highs when multiple compression risk is asymmetric—fair value reverts to $700-$900 if growth disappoints
• 3-5% position sizing is appropriate; a 10% position means 50% drawdown in LLY would cost 5% of total portfolio
• LLY dropped 15% from over $1,000 to $848 in six weeks during March-April—this actually happened, not theoretical
• RSI bearish divergence from 65.23 to 59.67 on marginal new high at upper Bollinger band $1,282 with below-average volume of 1.88M shares signals correction risk
• Net debt increased 50% from $30.4B to $46B in 18 months; debt-to-equity at 162% is leverage buildup not a war chest
• Q2 long-term debt issuance of $8.9B funded acquisitions at peak valuation—if multiple compresses, cost of capital rises when needed most
• 85% probability of no rate cuts keeps discount rates elevated, making high-multiple stocks vulnerable to compression
• Policy tail risks from IRA drug pricing reform, MFN proposals, Medicare negotiation expansion, and GLP-1 reimbursement battles are active threats
• 0.506 beta is backward-looking and understated current downside risk
• Conservative framework prioritizes surviving drawdowns to capture long-term gains, not being right about fundamentals while bleeding capital

→ vs aggressive: PEG ratio of 1.61 and 37% earnings growth cited as proof of mispricing ignores that at 42x trailing earnings, multiple compression risk is enormous while expansion is bounded; one bull case from Trefis does not insulate from 30% drawdown scenario to $700-900

→ vs aggressive: Position sizing increase from 3-5% to 7-10% is fundamentally dangerous—a 10% position in LLY would have cost the portfolio 1.5% in just six weeks during the March-April drawdown

→ vs aggressive: RSI divergence dismissed as a 'breather' is actually a textbook warning signal at resistance combining bearish momentum divergence, below-average volume, and upper Bollinger band contact

→ vs aggressive: Rising debt framed as a 'war chest' is actually a 50% debt increase to $46B with 162% debt-to-equity, with $8.9B issued in Q2 alone at peak valuation to fund acquisitions

→ vs aggressive: 'Higher for longer' argument is incomplete—elevated discount rates make high-multiple stocks vulnerable to compression in either direction, not just protection

→ vs aggressive: Dismissing policy risks as theoretical ignores active IRA drug pricing reform, Medicare negotiation expansion, and GLP-1 reimbursement battles that could compress multiples from 42x to 25x in a week

HOLD core position; add 3-5% new tranche at $1,200-$1,225 pullback with hard stop at $1,170 daily close; execute within 2-3 weeks

• TTM P/E of 42 makes the 1.61 PEG ratio less compelling than forward P/E of 26.6 suggests; haircutting growth by 20% makes the forward multiple look expensive
• March-April drawdown from $1,000+ to $848 in six weeks demonstrates low beta (0.506) is not a shield against meaningful drawdowns
• Bear case fair value of $700-$900 requires simultaneous multiple compression AND fundamental breakdown not visible in current data (47.7% revenue growth, 54% operating margins, 102% ROE, 91% Mounjaro growth)
• 8% recession odds creates a Goldilocks environment for quality compounders with self-funding balance sheets like LLY's $11B trailing free cash flow
• Pullback entry zone at $1,200-$1,225 is supported by confluence of 10 EMA (1,224), VWMA (1,202), and June breakout level (1,206)
• Hard stop at $1,170 daily close is appropriate as it sits below rising 50 SMA (1,178), which has become structural support
• IRA drug pricing reform is a real but unpriced tail risk; protect with position size limits, not avoidance
• Q3 2026 earnings is a key catalyst event where Mounjaro and Zepbound gross-to-net dynamics will be tested
• Correlation with other GLP-1 names and healthcare ETFs means effective concentration in the narrative is higher than LLY position alone suggests

→ vs aggressive: PEG of 1.61 is seductive but flawed at current 42x TTM P/E; growth math deteriorates significantly at higher multiples

→ vs aggressive: Position sizing to 7-10% contradicts the defensive/low-beta argument; cannot simultaneously claim half-market volatility and size like hypergrowth

→ vs aggressive: 'Smart money buying at all-time highs' is not supported by positioning data; $1.1T market cap crossing triggered profit-taking/distribution

→ vs conservative: Bear case ($700-$900) requires business deterioration not currently visible; these are tail scenario metrics, not base case

→ vs conservative: Rate environment is neutral to slightly positive for quality compounders, not purely a headwind; 85% no-cut probability means no rate drag on quality names

→ vs conservative: Waiting for 200 SMA at $1,051 creates open-ended trap; market structure won't give that discount without fundamental break visible in data